Chemotherapy for Primary Central Nervous System Lymphoma

Macarena I De La Fuente, Antonio M. Omuro

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In this chapter, commonly used chemotherapy regimens for primary central nervous system (CNS) lymphoma are discussed in the context of an overall approach to the disease. In the newly diagnosed setting, the mainstay of treatment remains methotrexate-based chemotherapy. Several effective multiagent methotrexate-based regimens have reported interesting results, although randomized studies are few. In the United States, the most common regimens are rituximab, procarbazine, vincristine, and cytarabine (R-MPV-A) and rituximab, methotrexate, temozolomide, cytarabine, and etoposide (R-MT-EA). Myeloablative chemotherapy regimens, particularly thiotepa, busulfan, and cyclophosphamide (TBC) followed by stem-cell transplant (ASCT) have emerged as powerful consolidation tools, although the optimal timing remains to be determined. The different available regimens will be discussed, with emphasis on efficacy and relative risks and benefits.

Original languageEnglish (US)
Title of host publicationHandbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages455-468
Number of pages14
ISBN (Print)9780128121009
DOIs
StatePublished - Apr 24 2018

Keywords

  • Chemotherapy for Primary Intraocular Lymphoma
  • High-dose chemotherapy with autologous stem-cell transplantation
  • High-dose methotrexate (MTX)
  • Intrathecal chemotherapy
  • Primary central nervous system lymphoma (PCNSL)

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Chemotherapy for Primary Central Nervous System Lymphoma'. Together they form a unique fingerprint.

Cite this